The Bispecific Antibody Boom Has A Manufacturing Problem: Here Is The Fix

The rapid expansion of bispecific antibody pipelines is straining traditional cell line development approaches, which often rely on random gene integration. These older methods struggle with the inherent complexity of multichain molecules, frequently leading to genetic instability, incorrect chain ratios, low productivity, and lengthy stability studies that delay clinical progress.

The article explains how newer, more controlled integration strategies can address these bottlenecks by ensuring that multiple antibody chains are inserted together in consistent ratios within transcriptionally active regions of host cells. This approach improves expression stability, increases titers, and enables more reliable scale‑up. In parallel, automated high‑throughput screening technologies allow thousands of clones to be evaluated simultaneously, dramatically shortening development timelines and enabling earlier, data‑driven decisions.

Together, these advances help align manufacturing capabilities with the growing demand for bispecific antibodies, supporting faster progression from discovery to the clinic while reducing risk across development programs.